Get started
Author

Yves Dutronc

Modulation of CD1d-restricted NKT cell responses by using N- acyl variants of α-galactosylceramides
2005 · Karl O. A. Yu, Jin S. Im, et al. · Proceedings of the National Academy of Sciences · 341
Overexpression of CD1d by Keratinocytes in Psoriasis and CD1d-Dependent IFN-γ Production by NK-T Cells
2000 · Brian Bonish, Denis Jullien, et al. · The Journal of Immunology · 218
PDF
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
2020 · Eric Simpson, Robert Bissonnette, et al. · Journal of the American Academy of Dermatology · 193
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
2017 · K. Reich, A. Pinter, et al. · British Journal of Dermatology · 193
PDF
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
2023 · Ohsang Kwon, Maryanne M. Senna, et al. · American Journal of Clinical Dermatology · 181
PDF
Prediction of Survival for Patients With Bullous Pemphigoid: A Prospective Study
2005 · Pascal Joly, Jacques Benichou, et al. · Archives of Dermatology · 168
The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
2020 · K.W. Wyrwich, H. Kitchen, et al. · British Journal of Dermatology · 134
PDF
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
2021 · Brett King, Justin Ko, et al. · Journal of the American Academy of Dermatology · 123
“‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata
2020 · Natalie V. J. Aldhouse, Helen Kitchen, et al. · Journal of Patient-Reported Outcomes · 117
PDF
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
2018 · Carle Paul, Christopher E.M. Griffiths, et al. · Journal of the American Academy of Dermatology · 102
Prevalence of genital psoriasis in patients with psoriasis
2018 · Kim A. P. Meeuwis, Alison Potts Bleakman, et al. · Journal of Dermatological Treatment · 92
PDF
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)
2022 · Thomas Bieber, Kristian Reich, et al. · British Journal of Dermatology · 87
PDF
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
2015 · R.G. Langley, P. Rich, et al. · Journal of the European Academy of Dermatology and Venereology · 84
Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
2020 · Kathleen W. Wyrwich, Helen Kitchen, et al. · American Journal of Clinical Dermatology · 74
PDF
Expansion and Hyperactivity of CD1d-Restricted NKT Cells during the Progression of Systemic Lupus Erythematosus in (New Zealand Black × New Zealand White)F1 Mice
2005 · Claire Forestier, Alberto Molano, et al. · The Journal of Immunology · 72
The CD1 family and T cell recognition of lipid antigens
2002 · Y. Dutronc, S.A. Porcelli · Tissue Antigens · 68
PDF
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial
2024 · Brett King, Justin Ko, et al. · JAMA Dermatology · 66
Métastase cutanée ombilicale (ou nodule de Sœur Mary Joseph) révélatrice d’un adénocarcinome ovarien
2000 · J.P Touraud, N Lentz, et al. · Gynécologie Obstétrique & Fertilité · 66
Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
2024 · M. Senna, A. Mostaghimi, et al. · Journal of the European Academy of Dermatology and Venereology · 64
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
2023 · Brett King, Jerry Shapiro, et al. · British Journal of Dermatology · 63
PDF
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
2022 · Brett King, Arash Mostaghimi, et al. · British Journal of Dermatology · 62
PDF
Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
2016 · A.B. Gottlieb, J.‐P. Lacour, et al. · Journal of the European Academy of Dermatology and Venereology · 57
PDF
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
2020 · Norman Wasel, Diamant Thaçi, et al. · Dermatology and Therapy · 46
PDF
Development of the Scalp Hair Assessment PRO™ measure for alopecia areata
2020 · K.W. Wyrwich, H. Kitchen, et al. · British Journal of Dermatology · 46
A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults.
2011 · Eric Simpson, Yves Dutronc · PubMed · 42
Works count: 97
Citation count: 3,079
H-index: 27
I10-index: 35
Year
Topic
Type